PHAT remains a Hold as VOQUEZNA revenue ramps and opex improves, but leverage, dilution and valuation risk persist.
Some unexpected paths include media and entertainment – such as streaming partnerships and music operations – climate and ...
According to Dr. Jennifer Levin Carter, MD, founder and CEO of Medzown, the concept of personalized medicine shifted from a ...
AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical GroupCompany founded by Frazier Life Sciences, which led the Series A financing with participation from ...
The Pharmaceutical Care Management Association (PCMA) has named David Marin, J.D., as its new president and CEO, effective ...
ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in ...
Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming ...
"3T is tackling one of the toughest challenges in immuno-oncology: delivering potent, selective TCR therapies for solid tumors," said Dr. Knudsen. "The science is compelling, and the opportunity for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback